Skip to Content

Guardant Health Inc GH Stock Quote

| Rating as of


Morningstar‘s Stock Analysis GH

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Guardant Turns in Solid Q3 and Awaits Key Trial Data; No Fair Value Estimate Change

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Guardant Health’s third-quarter sales roughly met expectations, but management trimmed its full-year guidance on several likely temporary challenges. We are not changing our $82 fair value estimate and continue to believe that shares in this liquid biopsy player remain undervalued. Our moat and trend ratings remain none and positive, respectively.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GH

Company Profile GH

Business Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

505 Penobscot Drive
Redwood City, CA, 94063
T +1 855 698-8887
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 1,373